Similarities and Differences of Hsp70, hsc70, Grp78 and Mortalin as Cancer Biomarkers and Drug Targets
Autor: | Amy L. Kennedy, Zitha Redempta Isingizwe, Rajani Rai, Pouya Javadian, Doris M. Benbrook |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
mortalin
QH301-705.5 cellular localization Review Biology Bioinformatics Cancer Vaccines Hsp70 combination therapy prevention Neoplasms medicine Biomarkers Tumor chaperone cancer Animals Humans HSP70 Heat-Shock Proteins Molecular Targeted Therapy Biology (General) HSPA8 Endoplasmic Reticulum Chaperone BiP Cellular localization HSPA9 HSC70 Heat-Shock Proteins Cancer General Medicine medicine.disease Biomarker (cell) Grp78 Chaperone (protein) hsc70 Cancer cell biology.protein biomarker Cancer biomarkers |
Zdroj: | Cells Cells, Vol 10, Iss 2996, p 2996 (2021) |
ISSN: | 2073-4409 |
Popis: | Background: Upregulation of Heath Shock Protein 70 (HSP70) chaperones supports cancer cell survival. Their high homology causes a challenge to differentiate them in experimental or prevention and treatment strategies. The objective of this investigation was to determine similarities and differences of Hsp70, hsc70, Grp78 and Mortalin members of the HSP70 family encoded by HSPA1, HSPA8, HSPA5 and HSPA9 genes, respectively. Methods: Literature reviews were conducted using HSPA1, HSPA5, HSPA8 and HSPA9 gene or protein names or synonyms combined with biological or cancer-relevant terms. Ingenuity Pathway Analysis was used to identify and compare profiles of proteins that directly bind individual chaperones and their associated pathways. TCGA data was probed to identify associations of hsc70 with cancer patient survival. ClinicalTrials.gov was used to identify HSP70 family studies. Results: The chaperones have similar protein folding functions. Their different cellular effects are determined by co-chaperones and client proteins combined with their intra- and extra-cellular localizations. Their upregulation is associated with worse patient prognosis in multiple cancers and can stimulate tumor immune responses or drug resistance. Their inhibition selectively kills cancer over healthy cells. Conclusions: Differences in Hsp70, hsc70, Grp78 and mortalin provide opportunities to calibrate HSP70 inhibitors for individual cancers and combination therapies. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |